FLT3 and acute myeloid leukemia: As an example, the approval of FLT3 inhibitors such as midostaurin or quizartinib may potentially change the risk-stratification associated with FLT3 mutation status, which is the most common mutation (approximately 30% of AML patients harbor a FLT3 mutation) associated with high risk in AML patients [22,23].